Description
Eve Technologies is proud to introduce the Human MSD® Discovery Assay® Brain Derived-pTau217 (MSDBDT217) — only recently released to the research community and widely regarded as a leading blood-based biomarker for Alzheimer’s disease. The assay delivers unmatched sensitivity and specificity on the Meso Scale Discovery® (MSD®) platform.
Why MSDBDT217?
-
Flagship Alzheimer’s biomarker: A next-generation marker for disease detection and monitoring.
-
Broad matrix compatibility: Validated for serum, plasma, and CSF, enabling true blood-based utility as well as CSF studies.
-
Available on the MSD® platform, which provides the femtogram-level sensitivity and analytical precision required.
-
New and unpublished: As this assay has only just become commercially available, no publications yet exist — be among the first to publish using BD-pTau217!
Accessible Innovation
Our per-well pricing model makes advanced biomarker testing accessible and affordable — ideal for cost-effective pilots and large-scale clinical studies. You pay only for the wells you use.
Trust Experience
With 20+ years of multiplex immunoassay expertise, Eve Technologies delivers:
-
CLIA-regulated quality systems and rigorous data standards
-
Publication-grade results with rapid turnaround
-
Reliability trusted by leading academic, clinical, and industry partners
Applications
-
Alzheimer’s disease and dementia research
-
Blood-based biomarker discovery and validation
-
Clinical trial endpoint development
-
Translational studies bridging CSF and blood
Ordering Information
-
Assay Name: Human MSD® Discovery Assay® Brain Derived-pTau217 (MSDBDT217)
-
Sample Types: Serum, Plasma, or CSF
-
Platform: MSD® (electrochemiluminescence detection)